Literature DB >> 21440264

Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma.

Morihito Okada1, Haruhiko Nakayama, Sakae Okumura, Hiromitsu Daisaki, Shuji Adachi, Masahiro Yoshimura, Yoshihiro Miyata.   

Abstract

OBJECTIVE: The detection rates of small lung cancers, especially adenocarcinoma, have recently increased. An understanding of malignant aggressiveness is critical for the selection of suitable therapeutic strategies, such as sublobar resection. The objective of this study was to examine the malignant biological behavior of clinical stage IA adenocarcinoma and to select therapeutic strategies using high-resolution computed tomography, fluorodeoxyglucose-positron emission tomography/computed tomography, and a pathologic analysis in the setting of a multicenter study.
METHODS: We performed high-resolution computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography in 502 patients with clinical T1N0M0 adenocarcinoma before they underwent surgery with curative intent. We evaluated the relationships between clinicopathologic characteristics and maximum standardized uptake values on fluorodeoxyglucose-positron emission tomography/computed tomography, ground-glass opacity ratio, and tumor disappearance rate on high-resolution computed tomography and component of bronchioloalveolar carcinoma on surgical specimens, as well as between these and surgical findings. We used a phantom study to correct the serious limitation of any multi-institution study using positron emission tomography/computed tomography, namely, a discrepancy in maximum standardized uptake values among institutions.
RESULTS: Analyses of receiver operating characteristic curves identified an optimal cutoff value to predict high-grade malignancy of 2.5 for revised maximum standardized uptake values, 20% for ground-glass opacity ratio, 30% for tumor disappearance rate, and 30% for bronchioloalveolar carcinoma ratio. Maximum standardized uptake values and bronchioloalveolar carcinoma ratio, tumor disappearance rate, and ground-glass opacity ratio mirrored the pathologic aggressiveness of tumor malignancy, nodal metastasis, recurrence, and prognosis, including disease-free and overall survival.
CONCLUSIONS: Maximum standardized uptake value is a significant preoperative predictor for surgical outcomes. High-resolution computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography findings are important to determine the appropriateness of sublobar resection for treating clinical stage IA adenocarcinoma of the lung.
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21440264     DOI: 10.1016/j.jtcvs.2011.02.007

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  21 in total

Review 1.  Pulmonary subsolid nodules: what radiologists need to know about the imaging features and management strategy.

Authors:  Hyungjin Kim; Chang Min Park; Jae Moon Koh; Sang Min Lee; Jin Mo Goo
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

2.  Adenocarcinoma containing lepidic growth.

Authors:  Hisashi Iwata
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer.

Authors:  Norifumi Tsubokawa; Yasuhiro Tsutani; Yoshihiro Miyata; Yoshinori Handa; Keizo Misumi; Hideaki Hanaki; Eisuke Hida; Morihito Okada
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

4.  The necessity of mediastinal lymph node resection for screen-diagnosed non-small cell lung cancer (NSCLC) manifesting as subsolid nodule.

Authors:  Sukki Cho
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

5.  Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan.

Authors:  Aritoshi Hattori; Kenji Suzuki; Takeshi Matsunaga; Mariko Fukui; Yukio Tsushima; Kazuya Takamochi; Shiaki Oh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-18

Review 6.  Controversies on lung cancers manifesting as part-solid nodules.

Authors:  Rowena Yip; Kunwei Li; Li Liu; Dongming Xu; Kathleen Tam; David F Yankelevitz; Emanuela Taioli; Betsy Becker; Claudia I Henschke
Journal:  Eur Radiol       Date:  2017-08-23       Impact factor: 5.315

7.  Segmentectomy versus lobectomy for clinical stage IA lung adenocarcinoma.

Authors:  Morihito Okada; Takahiro Mimae; Yasuhiro Tsutani; Haruhiko Nakayama; Sakae Okumura; Masahiro Yoshimura; Yoshihiro Miyata
Journal:  Ann Cardiothorac Surg       Date:  2014-03

8.  The impact on the prognosis of unsuspected N2 disease in non-small-cell lung cancer: indications for thorough mediastinal staging in the modern era.

Authors:  Ryosuke Tachi; Aritoshi Hattori; Takeshi Matsunaga; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki
Journal:  Surg Today       Date:  2016-07-21       Impact factor: 2.549

9.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

10.  Prediction of true-negative lymph node metastasis in clinical IA non-small cell lung cancer by measuring standardized uptake values on positron emission tomography.

Authors:  Tomoyoshi Takenaka; Tokujiro Yano; Yosuke Morodomi; Kensaku Ito; Naoko Miura; Daigo Kawano; Fumihiro Shoji; Shingo Baba; Koichiro Abe; Hiroshi Honda; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-08-03       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.